We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · June 29, 2020

Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis

European Journal of Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Neurology
Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-Year Update From the Open-Label Extension of the NEURO-TTR Trial
Eur. J. Neurol. 2020 Apr 28;[EPub Ahead of Print], TH Brannagan, AK Wang, T Coelho, M Waddington Cruz, MJ Polydefkis, PJ Dyck, V Plante-Bordeneuve, JL Berk, F Barroso, G Merlini, I Conceição, SG Hughes, J Kwoh, SW Jung, S Guthrie, M Pollock, MD Benson, M Gertz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading